Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2024 · New England Journal of Medicine · 129 citations
https://doi.org/10.1056/nejmoa2410316
N
Naoki Kashihara
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
510
Papers
13.5K
Citations
55
h-index
190
i10-index
Naoki Kashihara is an academic researcher from Kawasaki Medical School. The author has contributed to research in topics: Chronic Kidney Disease and Diabetes & Renal Diseases and Glomerulopathies & Dialysis and Renal Disease Management. The author has an h-index of 55, co-authored 434 publications.
ORCID: 0000-0002-9487-984XPapers by this author
worksSelective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species.
1992 · Proceedings of the National Academy of Sciences · 75 citations
https://doi.org/10.1073/pnas.89.14.6309
J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan
2020 · Scientific Reports · 68 citations
https://doi.org/10.1038/s41598-020-64123-z
The Japanese Clinical Practice Guideline for acute kidney injury 2016
2018 · Journal of Intensive Care · 59 citations
https://doi.org/10.1186/s40560-018-0308-6
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
2023 · Kidney International Reports · 55 citations
https://doi.org/10.1016/j.ekir.2023.01.041
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)
2020 · Clinical and Experimental Nephrology · 49 citations
https://doi.org/10.1007/s10157-020-01864-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat